Search

Your search keyword '"Maryam Shayan"' showing total 2 results
Start Over Author "Maryam Shayan" Journal molecular biology reports
2 results on '"Maryam Shayan"'

1. Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations

Author

Atiyeh Rezaei, Nazanin Momeni Roudsari, Mehrnoosh Hashemi, Maryam Shayan, Naser-Aldin Lashgari, Benyamin Pazoki, Roja Rahimi, Amir Hossein Abdolghaffari, Saeideh Momtaz, Ahmad Reza Dehpour, and Nadia Zandi

Subjects
0301 basic medicine, Invasive carcinoma, business.industry, Inflammatory Bowel Diseases, Context (language use), General Medicine, Opioid system, Cochrane Library, Bioinformatics, medicine.disease, digestive system, Inflammatory bowel disease, digestive system diseases, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Genetics, medicine, business, Molecular Biology
Abstract

Inflammatory bowel diseases (IBD) belong to a subgroup of persistent, long-term, progressive, and relapsing inflammatory conditions. IBD may spontaneously develop in the colon, resulting in tumor lesions in inflamed regions of the intestine, such as invasive carcinoma. The benefit of opioids for IBD treatment is still questionable, thereby we investigated databases to provide an overview in this context. This review demonstrates the controversial role of opioids in IBD therapy, their physiological and pharmacological functions in attenuating the IBD symptoms, and in improving inflammatory, oxidative stress, and the quality of life factors in IBD subjects. Data were extracted from clinical, in vitro, and in vivo studies in English, between 1995 and 2019, from PubMed, Google Scholar, Scopus, and Cochrane library. Based on recent reports, there are promising opportunities to target the opioid system and control the IBD symptoms. This study suggests a novel approach for future treatment of functional and inflammatory disorders such as IBD.

Published
2021
Full Text
View/download PDF

2. Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations

Author

Naser-Aldin, Lashgari, Nazanin Momeni, Roudsari, Nadia, Zandi, Benyamin, Pazoki, Atiyeh, Rezaei, Mehrnoosh, Hashemi, Saeideh, Momtaz, Roja, Rahimi, Maryam, Shayan, Ahmad Reza, Dehpour, and Amir Hossein, Abdolghaffari

Subjects
Clinical Trials as Topic, Anti-Inflammatory Agents, Analgesics, Opioid, Intestines, Disease Models, Animal, Mice, Oxidative Stress, Crohn Disease, Gene Expression Regulation, Receptors, Opioid, Quality of Life, Animals, Cytokines, Humans, Colitis, Ulcerative, Signal Transduction
Abstract

Inflammatory bowel diseases (IBD) belong to a subgroup of persistent, long-term, progressive, and relapsing inflammatory conditions. IBD may spontaneously develop in the colon, resulting in tumor lesions in inflamed regions of the intestine, such as invasive carcinoma. The benefit of opioids for IBD treatment is still questionable, thereby we investigated databases to provide an overview in this context. This review demonstrates the controversial role of opioids in IBD therapy, their physiological and pharmacological functions in attenuating the IBD symptoms, and in improving inflammatory, oxidative stress, and the quality of life factors in IBD subjects. Data were extracted from clinical, in vitro, and in vivo studies in English, between 1995 and 2019, from PubMed, Google Scholar, Scopus, and Cochrane library. Based on recent reports, there are promising opportunities to target the opioid system and control the IBD symptoms. This study suggests a novel approach for future treatment of functional and inflammatory disorders such as IBD.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results